4/23
08:09 am
vstm
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 [Yahoo! Finance]
Low
Report
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 [Yahoo! Finance]
4/23
07:30 am
vstm
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
Medium
Report
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
4/22
06:08 am
vstm
Verastem (VSTM) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Medium
Report
Verastem (VSTM) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
4/20
01:19 pm
vstm
Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
Low
Report
Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
4/20
12:56 am
vstm
Vectoring In On Verastem [Seeking Alpha]
Low
Report
Vectoring In On Verastem [Seeking Alpha]
4/11
01:00 am
vstm
Medium
Report
4/10
01:53 pm
vstm
Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
Low
Report
Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
4/10
01:29 pm
vstm
Verastem (VSTM) had its "buy" rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Verastem (VSTM) had its "buy" rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
4/10
07:00 am
vstm
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
Medium
Report
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
4/2
04:05 pm
vstm
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/30
11:54 am
vstm
Verastem (VSTM) had its "buy" rating reaffirmed by Jefferies Financial Group Inc.. They now have a $15.00 price target on the stock, down from $19.00.
Low
Report
Verastem (VSTM) had its "buy" rating reaffirmed by Jefferies Financial Group Inc.. They now have a $15.00 price target on the stock, down from $19.00.
3/19
03:33 pm
vstm
Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play [Seeking Alpha]
Low
Report
Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play [Seeking Alpha]
3/17
06:03 pm
vstm
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
Low
Report
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
3/17
05:08 pm
vstm
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers [Yahoo! Finance]
Medium
Report
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers [Yahoo! Finance]
3/17
04:44 pm
vstm
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers
Low
Report
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers
3/14
06:59 am
vstm
Verastem (VSTM) was upgraded by BTIG Research to "strong-buy".
Medium
Report
Verastem (VSTM) was upgraded by BTIG Research to "strong-buy".
3/12
08:03 am
vstm
Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
Low
Report
Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
3/5
01:08 pm
vstm
Verastem (VSTM) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Verastem (VSTM) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/5
12:18 pm
vstm
Verastem (VSTM) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Verastem (VSTM) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/5
04:11 am
vstm
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... [Yahoo! Finance]
Medium
Report
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... [Yahoo! Finance]
3/4
09:02 pm
vstm
Verastem Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Verastem Q4 Earnings Call Highlights [Yahoo! Finance]
3/4
07:23 pm
vstm
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
Medium
Report
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
3/4
06:37 pm
vstm
Verastem outlines 2026 milestones with CO-PACK franchise set to be self-sustaining in H2 [Seeking Alpha]
Medium
Report
Verastem outlines 2026 milestones with CO-PACK franchise set to be self-sustaining in H2 [Seeking Alpha]
3/4
06:37 pm
vstm
Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/4
04:01 pm
vstm
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
Medium
Report
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates